Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Technical Presentation (June 2021)
11 slides from Arbutus Biopharma's technical presentation, Jun 28, 2021
Slide 1: AB-729 Development Update EASL 2021 ILC
NASDAQ: ABUS www.arbutusbio.com AB - 729 Development Update EASL 2021 ILC TM Dr. Gaston Picchio Chief Development Officer June 28, 2021
Slide 2: Forward-Looking Statements
F o r w a r d - L oo kin g S ta t eme n t s This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - lookin
Slide 3: AB-729-001 Study Overview
AB - 729 - 00 1 Stud y O v e r vi e w Part 1: Single Ascending Dose in Healthy Subjects Dose 3 (360 mg) n=6; 4 active : 2 placebo (≥ Day 15 Safety) Dose 1 (60 mg) n=6; 4 active : 2 placebo Dose 2 (180 mg) n=6; 4 active : 2 placebo HBV DNA - Cohort B: 60 mg HBV DNA - Cohort C: 90 mg HBV DNA - (≥ Day
Slide 4: Baseline Characteristics
Ba s elin e Cha r ac t er i s t ic s Baseline Measure Cohort E AB - 729 60 mg Q4W* (N=7) Cohort F AB - 729 60 mg Q8W (N=7) Cohort I AB - 729 90 mg Q8W (N=6) Age in years, mean (range) 45.1 (33 – 63) 44.0 (31 – 59) 45.7 (38 – 54) Male gender, n (%) 4 (57%) 4 (57%) 4 (67%) BMI, mean (SD) 27.7 (5.01) 2
Slide 5: Repeat dosing results in comparable HBsAg decline profiles
Repeat dosing of AB - 729 60 mg and 90 mg results in comparable HBsAg decline profiles with 75 percent of subjects reaching <100 IU/mL Plateau in response observed around Week 20, regardless of dose or dosing interval AB - 729 60 mg Q4W [N=7] * AB - 729 60 mg Q8W [N=7] AB - 729 90 mg Q8W [N=6] *Due
Slide 6: No significant differences in mean HBsAg response between doses and intervals
There are no significant differences in mean HBsAg response between AB - 72 9 d os e s an d d os in g i n t e r v al s t o d a t e Visit Cohort E AB - 729 60 mg Q4W ܶ Cohort F AB - 729 60 mg Q8W Cohort I AB - 729 90 mg Q8W p value b e t w een Cohorts Week 16 - 1.44 ( - 0.71 to - 1.95) - 1.39 ( - 1.6
Slide 7: Repeat dosing of AB-729 was generally safe and well tolerated
Repeat dosing of AB - 729 was generally safe and well tolerated Subjects, n (%) Cohort E (60 mg Q4W*) [N=7] Cohort F (60 mg Q8W) [N=7] Cohort I (90 mg Q8W) [N=6] TOTAL [N=20] Subjects with any TEAE 4 (57) 5 (71) 1 (17) 10 (50) SAEs 0 0 0 0 Subjects with related TEAEs (all Grade 1) 2 (29) 4 (57) 1 (1
Slide 8: HBsAg reduction associated with increased HBV-specific immune responses
AB - 729 mediated HBsAg reduction is associated with increased HBV - specific immune responses in 3/5* evaluable subjects #2823
Slide 9: AB-729 is active against all isoforms of HBsAg
AB - 72 9 i s acti v e a g ain s t al l i so f o rm s * o f H B s A g From Thi, et al. Poster #2822, EASL 2021 *As measured with the RUO Abbott isoform assay MHB = medium HBsAg LHB = large HBsAg
Slide 10: AB-729 reduces HBV RNA in rapid and slow responders
AB - 72 9 r educe s H B V RN A i n r api d an d sl o w r esponde r s demon s t r a tin g broad target engagement From Thi, et al. Poster #282 3 , EASL 2021 #2822
Slide 11: Takeaways
Takeaways • Clinical data supports our view that AB - 729 60 mg every 8 weeks is an appropriate and convenient dose to explore in Phase 2a combination trials • Long - term dosing with AB - 729 results in 75 percent of subjects reaching <100 IU/mL of HBsAg , a clinically relevant threshold informing
Arbutus Biopharma — Technical Presentation (June 2021) on 6ix